Table 1 Comparison of clinical, laboratory and MRI features between NMO‐IgG‐positive OSMS and NMO‐IgG‐negative OSMS patients.
| NMO‐IgG positive | NMO‐IgG negative | p Value | ||
|---|---|---|---|---|
| Total (n = 14) | OSMS (n = 12) | OSMS (n = 7) | ||
| Age, years (SD) | 47 (15) | 49 (15) | 46 (14) | 0.642 |
| Age at onset, years (SD) | 36 (13) | 37 (13) | 36 (13) | 0.734 |
| EDSS, median (range) | 6.0 (2.0–8.0) | 6.0 (3.5–8.0) | 6.0 (0–6.5) | 0.217 |
| Transverse myelitis | 12 (86%) | 11 (92%) | 5 (71%) | 0.523 |
| Permanent complete blindness | 7 (50%) | 7 (58%) | 0 (0%) | 0.017 |
| CSF marked pleocytosis (>50 cells/μl) | 4 (29%) | 4 (33%) | 1 (14%) | 0.603 |
| OB | 2 (14%) | 2 (17%) | 0 (0%) | 0.509 |
| Serum ANA | 8/13 (62%) | 6/11 (55%) | 4 (57%) | >0.999 |
| MRI | ||||
| Long‐cord lesions (>3VS) | 13 (93%) | 12 (100%) | 4 (57%) | 0.036 |
| Cerebral lesions | 6 (43%) | 4 (33%) | 5 (71%) | 0.1698 |
ANA, anti‐nuclear antibodies; CMS, conventional form of multiple sclerosis; EDSS, Expanded Disability Status Scale; OB, oligoclonal IgG bands; OSMS, optic–spinal form of multiple sclerosis; p Value, compared between NMO‐IgG‐positive OSMS and NMO‐IgG‐negative OSMS using Mann–Whitney U test or Fisher's exact test; SMS, spinal form of multiple sclerosis; VS, vertebral segments.
Values in bold are significant (p<0.05).